We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Main Factors Driving Revenue Growth in Clinical Chemistry Identified

By LabMedica International staff writers
Posted on 04 May 2015
Print article
According to a report by Kalorama Information (New York, NY, USA), overall growth in the clinical chemistry market will be modest, driven mainly by new tests and demographic changes, including an aging population and increasing number of people at risk of cardiovascular disease, such as those with hypertension, diabetes mellitus, and abdominal obesity.

Kalorama’s report The Worldwide Market for In Vitro Diagnostic Tests covers clinical chemistry as well as the other major segments of clinical IVD testing.

The report includes market estimates for 2013 base year and forecasts to 2018. In addition to clinical chemistry, the other major IVD segments covered includes: Point-of-Care (POC) testing; Histology and Cytology; Lab-Based Infectious Disease Immunoassays by test; Molecular Assays; Hematology; Molecular Test Sales, Infectious Diseases; Lab-Based Immunoassay Sales by analyte type; Coagulation; Microbiology and Virology by Test Type; Blood Banking. Kalorama is currently conducting further research into the clinical chemistry market.

Kalorama expects modest growth in clinical chemistry despite predicted explosive growth in emerging markets such as India, China, and Brazil. This is because the US, Europe, and Japan account for at least 85% of the market and are expected to dominate for the next 5 years. Also, intense provider consolidation in the US, commoditization of most offerings, and increasing price pressures have pushed cost per test of routine chemistries about as low as possible.

“This is a mature market but there will be some growth, likely modest growth, from sales to emerging markets and expanding test menus,” said Bruce Carlson, publisher of Kalorama Information.

Despite the mature status of routine testing, the clinical chemistry market is continuously redefining itself via new test processes and menus. What growth will occur derives from new tests in lipid analysis, proteins, hormones and enzymes related to diabetes research, cardiovascular disease, cancer, and other acute and chronic conditions. The trend of adding new tests to the lab menu includes tests for homocysteine, anti-CCP, tumor markers, procalcitonin, Vitamin D, autoimmune ANAs, allergy, BNP, hsCRP, and hemoglobin A1c.

Clinical chemistry labs are challenged to add new tests with little increase in financial and human resources, in some cases even doing more with less. With cuts in government reimbursement rates, along with cost-cutting measures in general, clinical labs are exploring ways to improve productivity with smaller budgets. To survive, labs will need to run more tests in fewer sites, operate with less equipment, maintain lower operating costs, hire less skilled labor, and harness additional automation.

With increasing pressure to cut costs, top vendors and many central laboratories have invested in new systems that respond to the drive for automation to maintain or improve laboratory profitability. Automation optimizes efficiency and lowers errors by integrating mechanical, electronic, and informatics tools to perform various tasks.

Kalorama’s report is the result of extensive investigation via tracking of hundreds of companies for developments, trends, and financial results. This research is compiled with opinions, observations, and insights of experts to produce an unparalleled vision of the IVD industry. The information presented is derived on publicly available sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the IVD industry.

Related Links:

Kalorama Information
The Worldwide Market for In Vitro Diagnostic (IVD) Tests, 9th Edition




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.